In Vitro and in vivo 1H-MR spectroscopic examination of the renal cell carcinoma

International Journal of Biomedical Science

Volumn 8, Issue 2, 2012, Pages 94-108

  Sullentrop F ^a   Hahn, J ^a   Moka, Detlef ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

1H magnetic resonance spectroscopy; Lipid metabolism; Renal cell cancer

Indexed keywords

AGED; AMINO ACID METABOLISM; ARTICLE; BLOOD SAMPLING; CANCER CELL; CELL METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LIPID ANALYSIS; LIPID COMPOSITION; LIPID METABOLISM; MALE; PROTON NUCLEAR MAGNETIC RESONANCE;

EID: 84865380815     PISSN: 15509702     EISSN: 15552810     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Sufrin G, Chasan S, Golio A, Murphy GP. Paraneoplastic and serologic syndroms of renal adenocarcinoma. Sem. Urol. 1989; 7: 158.
2. 1H nuclear magnetic resonance spectroscopy. J. Pharm. Biomed. Anal. 1998; 17: 125-132.
3. 31P NMR spectroscopy of blood plasma: determination and quantification of phospholipid classes in patients with renal cell carcinoma. NMR Biomed. 2002; 15: 1-9.
4. Podo F, de Certaines JD. Magnetic Resonance Spectroscopy in Cancer: Phospholipid, neutral lipid and lipoprotein metabolism and function. Anticancer Res. 1996; 16: 1305-1316.
5. Smith ICP, Stewart LC. Magnetic resonance spectroscopy in medicine: clinical impact. Prog. Nucl. Mag. Res. Spec. 2002; 40: 1-34.
6. Ruiz-Cabello J, Cohen JS. Phospholipid metabolites as indicators of cancer cell function. NMR Biomed. 1992; 5: 226-233.
7. Engan T. Magnetic resonance spectroscopy of blood plasma lipoproteins in malignant disease: methological aspects and clinical relevance. Anticancer Res. 1996; 16: 1461-1472.
8. Karlsson KA, Samuelsson BE, Scherstén T, Steen GO, et al. The spingolipid composition of human renal carcinoma. Biochim. Biophys. Acta. 1974; 337: 349-355.
9. Gebhard RL, Clayman RV, Prigge WF, Figenshau R, et al. Abnormal cholesterol metabolism in renal clear cell carcinoma. J. Lipid Res. 1987; 28: 1177-1184.
10. Clayman RV, Bilhartz LE, Spady DK, Buja LM, et al. Low density lipoprotein-receptor activity is lost in vivo in malignantly transformed renal tissue. FEBS Lett. 1986; 196: 87-90.
11. Rudling M, Collins VP. Low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA levels are coordinately reduced in human renal cell carcinoma. Biochim. Biophys. Acta. 1996; 1299: 75-79.
12. Sakakibara N, Gasa S, Kamio K, Makita A, et al. Association of elevated sulfatides and sulfotransferase activities with human renal cell carcinoma. Cancer Res. 1989; 49: 335-339.
13. Kobayashi T, Honke K, Kamio K, Sakakibara N, et al. Sulfolipids and glycolipid sulfotransferase activities in human renal cell carcinoma cells. Br. J. Cancer. 1993; 67: 76-80.
14. Gasa S, Casl MT, Makita A, Sakakibara N, et al. Presence and characterization of glycolipid sulfotransferase in human cancer serum. Eur. J. Biochem. 1990; 189: 301-306.
15. Talley DJ, Sadowski JA, Boler SA, Li JJ. Changes in lipid profiles of estrogen-induced and transplanted renal carcinomas in syrian hamsters. Int. J. Cancer. 1983; 32: 617-621.
16. Moka D, Vorreuther R, Schicha H, Spraul M, et al. Magic angle spinning proton nuclear magnetic resonance spectroscopic analysis of intact kidney tissue samples. Anal. Comm. 1997; 34: 107-109.
17. 1H magic angle spinning (MAS) NMR spectra. NMR Biomed. 2000; 13: 64-71.
18. 31P high-resolution NMR study. NMR Biomed. 1999; 12: 1-6.
19. 31P NMR spectroscopy to monitor chemotherapy-associated changes of serum phospholipids in patients with malignant lymphomas. Magn. Reson. Med. 1996; 35: 449-456.
20. 31P MRS spectra of sera from patients with multiple myeloma. NMR Biomed. 1995; 8: 127-132.
21. 31P-MRS (magnetic resonance spectroscopy) spectra of sera from patients with acute leukemia. Biochim. Biophys. Acta. 1997; 1360: 71-83.
22. 31P NMR spectroscopy in clinical analysis of changes of serum phospholipids in leukemia, lymphoma and some other non-haematological cancers. Anticancer Res. 1996; 16: 1587-1594.
23. Inoue Y, Yoshikawa K, Yoshioka N, Watanabe T, et al. Evaluation of Renal Function with 99mTc-MAG3 Using Semiautomated Region of Interest. J. Nucl. Med. 2000; 41: 1947-1954.
24. 13C enriched metabolites form cell suspensions incubated in deuterated media. Magn. Reson. Med. 1996; 36: 359-365.
25. 13C NMR Spectroscopy of Human Blood Plasma. Anal. Chem. 1995; 67: 793-811.
26. Kim DY, Kim KB, Kim OD, Kim JK. Localized in vivo proton spectroscopy of renal cell carcinoma in human kidney. J. Korean. Med. Sci. 1998; 13: 49-53.
27. Garrod S, Humpfer E, Spraul M, Sonnor SC, et al. Magn. Res. Med. 1999; 41: 1108-1118.
28. Star-Lack JM, Adalsteinsson E, Gold GE, Ikeda DM, et al. Magn. Reson. Med. 2000; 43: 325-330.
29. Babin F, Abderrazik M, Favier F, Cristol JP, et al. Differences between polyunsaturated fatty acid status of non-institutionalised elderly women and younger controls: a bioconversion defect can be suspected. Eur. J. Clin. Nutr. 1999; 53 (8): 591-596.
30. De Groot RH, van Boxtel MP, Schiepers OJ, Hornstra G, et al. Age dependence of plasma phospholipid fatty acid levels: potential role of linoleic acid in the age-associated increase in docosahexaenoic acid and eicosapentaenoic acid concentrations. Br. J. Nutr. 2009 Oct; 102 (7): 1058-1064.
31. Garrod S, Humpfer E, Spraul M, Connor SC, et al. Magn. Res. Med. 1999; 41: 1108-1118.
32. Star-Lack JM, Adalsteinsson E, Gold GE, Ikeda DM, et al. Magn. Reson. Med. 2000; 43: 325-330.
33. Breier C, Lisch HJ, Drexel H, Braunsteiner H. Lipoproteins, apolipoproteins, lipoprotein lipase, hepatic triglyceride lipase and lecithin cholesterol acyltransferase in patients with nephrotic syndrome. Schweiz. Med. Wochenschr. 1983; 113: 909-913.
34. 13CNMR lipid profiles of human renal tissues. Biopolymers. 2003; 72 (2): 86-95.
35. Kobayashi T, Honke K, Kamio K. Sulfolipids and glycolipid sulfotransferase activities in human renal cell carcinoma cells. Br. J. Cancer. 1993; 67: 76-80.